When does invokana go generic?

When does Invokana (canagliflozin) go generic in the US?

Invokana (canagliflozin) is an SGLT2 inhibitor by Janssen (J&J). Generic versions are not tied only to the end of a company’s “marketing exclusivity”; they typically depend on when key patents and related exclusivities expire and whether challengers successfully enter the market.

DrugPatentWatch.com tracks Invokana’s patent landscape and points to the timing when exclusivity/patents may allow generic entry. You can check the latest “generic timeline” there for the most current dates and any updates from patent litigation or filings: DrugPatentWatch – Invokana (canagliflozin).

What could delay generic entry even after a patent expires?

Even when one or more patents expire, generic launches can still be delayed by:
- Other still-active patents listed in the Orange Book (method-of-use, formulation, or combination patents).
- Ongoing patent litigation that affects “at-risk” launch dates.
- Regulatory exclusivities that can extend beyond patent expiration for certain indications.

DrugPatentWatch’s Invokana patent detail pages are useful for seeing which specific patents are likely driving the latest possible generic entry window. [1]

How to check the exact date for “generic” (not just patent expiry)

People often mean different dates by “go generic,” such as:
- The first day a manufacturer can legally market a generic (after relevant patents/exclusivities).
- The first day a generic product actually appears on pharmacy shelves (commercial launch timing).

DrugPatentWatch is a good starting point because it links the patent/exclusivity framework to the likely earliest generic launch window. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/brands/invokana